The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

American Cancer Society plans to double research budget in five years

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE AMERICAN CANCER SOCIETY plans to double its annual funding for research by 2021. The society made the announcement in conjunction with Vice President Biden’s National Cancer Moonshot Summit at Howard University in Washington, D.C.

ACS plans to increase its annual research investment to approximately $240 million by 2021. The organization currently spends about $100 million per year in new grants to academic research institutions and another $15 to $20 million annually in research by ACS investigators in cancer epidemiology, surveillance and health services, behavioral research, and economics and health policy.

ACS has invested $4.5 billion in research since 1946. According to the society, 47 of its funded researchers have won Nobel Prizes for their work.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
By Deborah Phippard
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account